HIF1A and myelodysplastic syndrome: A recent study has reported that lenalidomide, which is approved for the treatment of MM and myelodysplastic syndromes associated with deletion of the long arm of chromosome 5q, inhibited hypoxia-induced endothelial cell cord formation and HIF-1α accumulation [30].